Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lundbeck Still Assessing Future Of Antipsychotic After Phase III Failure, Says CEO

Executive Summary

Deborah Dunsire, Lundbeck’s new CEO, talks to Scrip about the fallout from its recent Phase III setback, and how she sees the road ahead for CNS clinical research.

You may also be interested in...



Lundbeck Boosts US R&D Capability With $400m Abide Theraputics Bid

Danish neuroscience company plans to acquire Abide Therapeutics for $250m upfront and up to $150m in milestones to access serine hydrolase drug discovery platform.

The Darkest Hour Is After DAYBREAK For Lundbeck’s New Antipsychotic

The first Phase III study for Lundbeck’s novel antipsychotic flops leaving the Danish company shares down by 25% as investors wonder what’s left in the pipeline.

Finance Watch: Karuna, Cerevel And Others Benefit From Improving Biotech Sentiment

Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC124190

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel